Related references
Note: Only part of the references are listed.Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503
Lori Rice et al.
MICROVASCULAR RESEARCH (2011)
BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
Yao Dai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
Neru Munshi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis
Marion Zillhardt et al.
NEOPLASIA (2010)
MET receptor tyrosine kinase as a therapeutic anticancer target
Christine M. Stellrecht et al.
CANCER LETTERS (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Gretchen M. Schroeder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Sean G. Buchanan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
Michalis V. Karamouzis et al.
LANCET ONCOLOGY (2009)
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
Weon-Kyoo You et al.
BMB REPORTS (2008)
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
Z. Tang et al.
BRITISH JOURNAL OF CANCER (2008)
Molecular cancer therapy: Can our expectation be MET?
Cristina Migliore et al.
EUROPEAN JOURNAL OF CANCER (2008)
Expression and Mutational Analysis of MET in Human Solid Cancers
Patrick C. Ma et al.
GENES CHROMOSOMES & CANCER (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The MET receptor tyrosine kinase in invasion and metastasis
Silvia Benvenuti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma
A. T. Liao et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2007)
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
P. C. Ma et al.
BRITISH JOURNAL OF CANCER (2007)
Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1
Giuliana Cassinelli et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Opinion -: Invasive growth:: a MET-driven genetic programme for cancer and stem cells
Carla Boccaccio et al.
NATURE REVIEWS CANCER (2006)
Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion
SY Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Targeting the c-Met pathway potentiates glioblastoma responses to γ-radiation
BC Lal et al.
CLINICAL CANCER RESEARCH (2005)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
G Maulik et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
A novel germ line juxtamembrane Met mutation in human gastric cancer
JH Lee et al.
ONCOGENE (2000)
Share Paper
